Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study

Lignende værker

• Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results
  af: Smolen, Josef S., et al.
  Udgivet: (2017)
• A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
  af: Choe, Jung-Yoon, et al.
  Udgivet: (2017)
• Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty‐Two–Week Phase III Randomized Study Results
  af: Weinblatt, Michael E., et al.
  Udgivet: (2018)
• Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis
  af: Weinblatt, Michael E., et al.
  Udgivet: (2017)
• Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
  af: Ebbers, Hans C., et al.
  Udgivet: (2020)